ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer—A Multicenter Study

Excerpt

Recurrence is a common event in high-grade serous ovarian cancer (HGSOC), and it is often managed with systemic treatment. The role of secondary cytoreductive surgery still is debated. Some retrospective studies advocate in favor of this procedure, with only two randomized trials showing controversial results.1,2 The presence of a deleterious BRCA mutation is regularly investigated and used as a driver for the management of women with HGSOC at either primary diagnosis or recurrence. Although it is a recognized prognostic and predictive factor3,4 only few studies have investigated the correlation between surgical treatment and BRCA mutation status at recurrence. This study aimed to explore the hypothesis that BRCA mutation status can have an impact on either disease presentation or efficacy of secondary cytoreductive surgery at the time of recurrence. …